Biocon to take on Roche Pharma with its psoriasis drug to treat moderate to severe Covid patients

​​The company is marketing the drug as a replacement to Roche’s tocilizumab (originally approved for rheumatoid arthritis) that is currently in off-label use among Covid-19 patients who suffer from cytokine release syndrome (CRS).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2ZqsLMg
via IFTTT